{"id":"W2954573235","doi":"10.1097/01.ogx.0000458794.60509.a8","title":"Anti-Angiopoietin Therapy With Trebananib for Recurrent Ovarian Cancer (TRINOVA-1)","year":2014,"lang":"en","type":"article","venue":"Obstetrical & Gynecological Survey","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Bevacizumab; Ovarian cancer; Adverse effect; Angiogenesis; Vascular endothelial growth factor; Oncology; Internal medicine; Progression-free survival; Cancer; Endometrial cancer; Chemotherapy; Gastroenterology; VEGF receptors","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008468009,0.0004207569,0.001407399,0.0003639466,0.0002295997,0.0003802246,0.000391525,0.0006874769,0.002621315],"category_scores_gemma":[0.0007237238,0.0003147379,0.001109769,0.0002764619,0.0003635812,0.0004519545,0.0002529501,0.001216252,0.0003847496],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003590611,"about_ca_system_score_gemma":0.0005149841,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003469928,"about_ca_topic_score_gemma":0.001196379,"domain_scores_codex":[0.9997266,0.0001284923,0.0000261951,0.00004113816,0.0000285313,0.00004901601],"domain_scores_gemma":[0.9996994,0.00007150539,0.00009185372,0.00001915968,0.00001483949,0.0001032674],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7496727,0.02041862,0.007889895,0.001699103,0.001605598,0.0002940575,0.0001303052,0.001451471,0.02489512,0.0003392657,0.002576223,0.1890277],"study_design_scores_gemma":[0.5719228,0.3966723,0.02083942,0.00009827448,0.0007099426,0.0004220085,0.00003502687,0.000831552,0.003403312,0.0001832879,0.004852325,0.00002981906],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.990371,0.004996323,0.0003267075,0.0002798494,0.0001666908,0.002075493,0.0004674243,0.00008877186,0.001227753],"genre_scores_gemma":[0.9914092,0.002417423,0.0009388268,0.0005946361,0.0001440061,0.002213668,0.000640071,0.000008391201,0.001633774],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002621315,"threshold_uncertainty_score":0.008769214,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0637762528799003,"score_gpt":0.3192112720024464,"score_spread":0.2554350191225461,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}